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The UK audit was undertaken in primary breast cancer patients receiving adjuvant chemotherapy to: (1) record the incidence of
neutropenic events (hospitalisation due to febrile neutropenia, dose delay of X1 week or dose reduction of X15% due to
neutropenia); (2) evaluate the impact of neutropenic events on overall dose intensity (DI) received and (3) review the use of
granulocyte colony-stimulating factor (G-CSF) in clinical practice. Data from 422 patients with Stage I–III breast cancer were
collected from 15 centres. Cyclophosphamide, methotrexate and 5-fluorouracil(CMF)- or anthracycline-based regimens were the
most commonly used. Only 5.2% of patients received G-CSF. Overall, 29% of patients experienced a neutropenic event, most
frequently dose delay. Neutropenic events had a significant impact on the ability to deliver planned DI. Out of 422 patients, 17% did
not achieve 85% of their planned DI; due to neutropenia in 11% of patients. Of the neutropenic patients receiving CMF- or
anthracycline-based regimens, around 40 and 32% of patients, respectively, did not achieve 85% of their planned DI. Patients who
experienced one neutropenic event had a higher risk of a second event. During adjuvant chemotherapy of primary breast cancer,
neutropenic events are common, likely to occur in subsequent chemotherapy cycles, and have a significant impact on receiving
planned DI.
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Adjuvant chemotherapy is a well-established treatment modality
for patients with high-risk primary breast cancer, and has a
beneficial impact on survival (Early Breast Cancer Trialists’
Collaborative Group, 1998). In order to obtain this benefit,
maintaining scheduled chemotherapy dose intensity (DI) is an
important factor: both retrospective and prospective studies
suggest that as DI is decreased, treatment outcome may be
compromised. Bonadonna et al (1995) reviewed the results of
therapy based on the percentage of projected dose of cyclopho-
sphamide, methotrexate and 5-fluorouracil (CMF) received in the
first Milan adjuvant trial, which involved over 300 patients.
Survival was worse in those patients who received less than 85% of
the projected dose of treatment (Bonadonna et al, 1995).
Furthermore, patients who received o65% of their projected dose
had similar survival rates as patients who received no chemother-
apy at all. This was, however, a retrospective analysis and some of
these patients may have performed poorly because of confounding
factors such as medically significant comorbidities, which also may
have had an impact on survival.
Prospective studies have evaluated the impact of chemotherapy
dose and DI on clinical outcome. The CALGB 8541 study evaluated
three different DI levels (low, moderate and high) of cyclopho-
sphamide, adriamycin and fluorouracil (CAF) in over 1500 women
with node-positive Stage II breast cancer (Wood et al, 1994). One
group received cyclophosphamide 400mgm
 2 of body-surface
area and 40mgm
 2 of adriamycin once every 28 days and
400mgm
 2 of fluorouracil twice every 28 days, for six cycles.
Another group received 50 percent higher doses of the three drugs
(600, 60 and 600mg, respectively) but for only four cycles, so that
the total dose was identical in these two groups, but the DI was
higher in the second. The third group received half the total dose
used in the other two groups and at half the DI used in the second
group. Overall survival (OS) at 9-year follow-up was significantly
improved in those women receiving CAF at moderate or high DI vs
those receiving a lower DI (Budman et al, 1998). The lowest dose
level in the trial was therefore likely to have been below the
minimum effective threshold dose and above this level there was
little evidence of a DI effect. Data from a 5-year follow-up study of
women with poor prognosis, node-positive breast cancer also
suggested that OS and disease-free survival were significantly
improved in women receiving FEC regimens (fluorouracil,
epirubicin and cyclophosphamide) containing a higher dose of
epirubicin (100mgm
 2) compared with those receiving regimens
containing only 50mgm
 2 of epirubicin (The French Adjuvant
Study Group, 2001).
Despite the evidence that indicates the benefits of maintaining
planned DI, doses are often reduced or delayed in clinical practice.
This is undertaken to minimise the toxic sequelae of treatment in Received 2 January 2003; revised 21 July 2003; accepted 23 July 2003
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lpatients whose blood counts have not adequately recovered
(Hayes, 2001). Although such dose reductions often result in
minimal decreases in toxicity, they may have a significant impact
on reducing the relative DI (RDI) of treatment received (Hayes,
2001). As a result, survival outcomes may be compromised. For
example, if a patient is due to receive six cycles of chemotherapy
and on cycle two, doses are reduced by 25%, assuming that this
level of dose reduction is maintained, the patient will only have
received 79% of the initial planned dose at the completion of
therapy (Table 1a). Similarly, a delay in chemotherapy delivery
reduces the DI received (Table 1b). It has been calculated that each
7-day delay results in an approximate 5% decrease in the DI
(Longo et al, 1991).
In addition to dose modifications, severe neutropenia can lead
to febrile episodes, and to the possible requirement for hospita-
lisation and i.v. antibiotic treatment. Neutropenia, therefore, also
has an impact upon both morbidity and the cost of treatment
(Seifeldin and Schultz, 1998). There are variations in the degree of
neutropenia experienced, depending on the chemotherapy regi-
men used (Gurney, 1989). However, there are limited data to
indicate the number of breast cancer patients actually affected by
severe neutropenia in clinical practice, and the magnitude of its
effect on overall DI received (Dranitsaris and Tran, 1995; Hayes,
2001). For example, we are not aware of any previous data relating
to patients treated within the UK. The UK neutropenia audit was
initiated to evaluate the extent to which neutropenic complications
were encountered in clinical practice and affect the ability to
deliver planned chemotherapy in the adjuvant treatment of
primary breast cancer. As there is evidence that the chemotherapy
regimen employed is an important factor relative to outcome
(Levine et al, 1998), the range of regimens currently employed was
recorded in this audit.
The use of granulocyte colony-stimulating factor (G-CSF), which
stimulates neutrophil recovery after chemotherapy and thus
alleviates drug-induced neutropenia, may allow the delivery of
chemotherapy as scheduled in patients with breast cancer (de
Graaf et al, 1996). Data regarding the extent and impact of the use
of G-CSF in the adjuvant treatment of primary breast cancer in the
UK are also limited. This was also evaluated in this audit.
MATERIALS AND METHODS
Patients and centres
Both district general and teaching hospitals across the UK, with a
breast cancer practice and available staff to complete records, were
asked to participate in the audit. Data were collected in relation to
patients in whom adjuvant chemotherapy for primary breast
cancer (Stages I–III) was being initiated. We aimed to involve 15
centres and collect data from 400 patients.
Data collection
Generally, data were collected prospectively using either a
preprogrammed psion palm top computer or paper records.
Patient details were recorded, including height, weight, date of
birth, diagnosis, stage of disease and prior or concomitant
radiotherapy (yes/no). The planned treatment protocol was
recorded prior to the start of therapy and the actual treatment
given were then recorded for each cycle, after it had been
administered. Any delay in administration of chemotherapy and
the reasons for this were recorded, as was the absolute neutrophil
count (ANC) at the time of the delay, and whether the patient had
experienced neutropenia during that cycle. A ‘trigger’ ANC at
which doses were delayed or reduced was not specified in the
protocol. As the audit reflects current clinical practice, ANC
thresholds for dose delay/reduction varied from centre to centre.
When the dose of chemotherapy administered was less than that
planned, the reason for the dose reduction and the percentage of
planned dose given were recorded.
All hospitalisations, their causal relation to neutropenia, the
temperature and ANC on admission, and the length of hospital
stay were recorded. Use of haematopoietic growth factors (dose,
frequency of administration, total number of doses and reason for
administration) was also recorded.
In some centres, prospective data collection was not possible
and data were collected retrospectively from patient notes (40%).
Data were collected for the cycles up until a patient discontinued
or switched therapy and the RDI calculated relative to what they
would have received up until that time. Data collected from each
centre were entered onto a central database. Each patient record
was checked for anomalies in data entry or any missing data and
these were referred back to the centre for validation.
Data evaluation
The primary objective of the audit was to record the incidence of
neutropenic events and to evaluate their impact on RDI received.
Secondary objectives were to evaluate the impact of a neutropenic
event on the risk of further neutropenic events in subsequent
cycles, and to record the use of G-CSF in clinical practice.
Neutropenic events were defined as: hospitalisation due to
febrile neutropenia; dose delay of X1 week due to neutropenia;
and/or dose reduction of X15% due to neutropenia.
Dose intensity is defined as the amount of drug delivered per
unit time, generally expressed as mgm
 2week
 1, and RDI is the
amount of drug (or average amount of drugs for a combination
regimen) delivered per unit time compared with an arbitrarily
chosen regimen (Hryniuk, 1998). In this audit, RDI was
determined as the decimal fraction of the ratio of the regimen
delivered to the planned regimen, as follows:
Dose given
Doseplanned

Actualcycledays
Plannedcycledays
Statistical analyses
Data are presented as descriptive statistics. Statistical analysis of
the impact of neutropenic events on RDI and a comparison of
Table 1a Impact of dose reductions on dose delivered
Dose reduction (%)
No dose reduction 20 25 50
Dose delivered
a (% planned)
Cycle 1 100 80 75 50
Cycle 2 100 83 79 58
Cycle 3 100 87 83 67
Cycle 4 100 90 88 75
Cycle 5 100 93 92 83
Cycle 6 100 97 96 92
aAssuming that this level of dose reduction is maintained until completion of therapy.
Bold values signify that survial outcomes may be compromised.
Table 1b Impact of dose delay on dose intensity
Days delay over course % projected dose intensity
a
0 100
79 5
14 90
21 86
28 82
35 78
42 75
aAssumes that full doses were given in each cycle. Thus, a 1-week delay lowers the %
projected dose intensity by approximately 5%.
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neutropenic events were performed using either a one-tailed z-
test or a two-tailed t-test. Values in the one-tailed z-test were
considered significant at the 5% level (Po0.05) if the test statistic
was greater than 1.64 standard errors (s.e.) above the mean. Values
in the two-tailed t-test were considered significant at the 5% level
(Po0.05) if the test statistic was greater than 1.96s.e. either above
or below the mean.
RESULTS
Patients and centres
The period of data collection was from June 1997 to June 1999.
Data were collected in relation to 422 patients with Stage I – III
breast cancer from 15 centres, including both district general and
teaching hospitals across the UK.
Characteristics of the patients included in the audit are
presented in Table 2. The majority of patients had Stage II disease
and the median number of positive nodes was 1.
A wide variety of chemotherapy regimens was administered
(Table 3a and b), with 61% of patients receiving CMF-based
regimens and 39% receiving anthracycline-based regimens. The
median age of patients receiving CMF- and anthracycline-based
regimens was 49.4 and 48.1 years, respectively.
Incidence of neutropenic events – all patients
Of the 422 patients, 121 (29%) experienced at least one neutropenic
event (Table 4). The median ANC at which chemotherapy was
delayed or reduced was 0.9 10
9 l
 1 (range 0.20–1.8 10
9l
 1).
Although a greater percentage of patients who experienced a
neutropenic event were receiving concomitant radiotherapy, the
impact of this intervention did not significantly affect the risk of
neutropenic events. Of the 121 patients with a neutropenic event,
44% received concomitant radiotherapy compared with 33% of the
301 patients who did not experience a neutropenic event (P¼NS).
Overall, out of the 422 patients in the audit, 17% of patients did not
achieve 85% of their planned DI; due to neutropenia in 11% of
patients. The mean RDI was significantly lower (Po0.01) in those
who experienced a neutropenic event compared with those
patients who did not.
A small percentage (5.2%) of patients received a haematopoietic
growth factor, which in all cases was G-CSF. Granulocyte colony-
stimulating factor was administered either to hospitalised patients
as treatment for febrile neutropenia (1.7%), or to nonhospitalised
patients who had experienced a neutropenic event in a previous
cycle (as secondary prophylaxis) to avoid further complications
(3.6%). Granulocyte colony-stimulating factor was given for
between 1 and 8 days. On average, G-CSF was given for longer
(6.3 vs 1.4 days) and over more cycles (2 vs 1 cycle) when
administered as secondary prophylaxis. Owing to the small
number of patients receiving G-CSF, further evaluation of this
group was not considered appropriate.
As the majority of patients involved in the audit received CMF-
or anthracycline-based regimens, further evaluation was per-
formed specifically on these two groups of patients.
Incidence of neutropenic events – CMF-based regimens
Overall, 29% of patients receiving CMF-based regimens experi-
enced a neutropenic event. Table 4 shows the incidence of
neutropenic events in patients receiving specific CMF-based
regimens. Dose delay was the most frequent (occurring in 23%
of patients) followed by dose reduction (8% of patients) and
hospitalisation (5% of patients). Dose delay due to neutropenia
was also the most common neutropenic event for each individual
CMF-based regimen. The incidence of neutropenic events was
highest in those receiving 3-weekly intravenous CMF.
The incidence of neutropenic events by cycle in patients
receiving CMF-based regimens is shown in Figure 1, with the
overall incidence of neutropenic events tending to increase with
cycle number. For all cycles, the majority of neutropenic events
were dose delays and the incidence of hospitalisation was low. The
median cycle delay due to neutropenia was 7 days and the median
dose reduction due to neutropenia was 26.8%.
The impact of neutropenic events on RDI for patients receiving
CMF-based regimens is shown in Figure 2. Patients receiving G-
CSF as prophylaxis (n¼17) were excluded from this analysis.
Patients who experienced neutropenic events received a signifi-
cantly lower mean RDI than those who did not experience
neutropenic events (86.9 vs 95.7%, Po0.01). The median (range)
RDI was 88% (58.5–125.9%) and 98.8% (67–110%) for patients
who experienced and who did not experience neutropenic events,
respectively. Almost 40% of patients with neutropenic events did
not achieve 85% of the planned DI, compared with 9% of patients
in the group with no complications. However, only 3% of patients
experiencing neutropenic events were not able to achieve 70% of
the planned RDI.
Table 2 Baseline demographic characteristics of patients in the audit
Characteristic Mean (range)
Age (years) 49.3 (22.8–68.8) (n¼408)
a
Height (cm) 161.8 (131–198) (n¼380)
a
Weight (kg) 69.9 (40–131) (n¼390)
a
Stage of disease
I8 0
II 254
III 88
Prior radiotherapy
Yes 8%
No 91% (1% unknown)
a
Concomitant radiotherapy
Yes 36%
No 64%
Number of positive nodes 3.17 (0–33) (n¼398)
a
(median value¼1.00)
aData not available for all 422 patients enrolled in the audit.
Table 3a Breast cancer patients Stages I – III by regimen
Patients Stage I Stage II Stage III Total
Regimens %nn n n
CMF (oral) day 1 – 8 28 29 76 14 119
CMF (i.v.) day 1 – 8 16 10 35 22 67
CMF (3 weekly) 17 15 50 6 71
AC 12 4 31 14 49
Adriamycin/CMF 11 1 26 18 45
FEC 8 19 16 1 36
NEAT 3 2 8 3 13
Adriamycin 2 0 7 2 9
CAF 1 0 3 4 7
Epirubicin/CMF o10 2 13
Other o10 0 33
Total 100 80 254 88 422
CMF¼Cyclophosphamide, methotrexate and 5-fluorouracil; AC¼anthracydine;
FEC¼fluorouracil, epirubicin and cyclophosphamide; CAF¼cyclophosphamide,
adriamycin and fluorouracil. Other¼epirubicin, epirubicin/cyclophosphamide or
docetaxel.
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regimens
Overall, 28% of patients receiving anthracycline-based regimens
experienced a neutropenic event. Dose delay was again the most
common event (occurring in 21% of patients), followed by
hospitalisation (8.5% of patients) and dose reduction (5.5% of
patients).
Table 4 shows the incidence of neutropenic events recorded in
patients receiving specific anthracycline-based regimens. For all
Table 3b Details of planned chemotherapy regimens used in the audit
Drug (dose (mg m
 2)/administration route/days given/(cycle length))
Regimen Cyclophosphamide Methotrexate 5-FU Adriamycin Epirubicin
CMF/oral 100 p.o. 40 i.v. 600 i.v.
(6 cycles) d1–14 d1, d8 d1, d8
(28d cycle) (28d cycle) (28d cycle)
CMF/i.v. 600 i.v. 40–50 i.v. 600 i.v.
(6 cycles) d1, d8 d1, d8 d1, d8
(28d cycle) (28d cycle) (28d cycle)
CMF 3-weekly 600–750 i.v. 40 i.v. 600 i.v.
(5 – 8 cycles) d1 d1 d1
(21d cycle) (21d cycle) (21d cycle)
AC 600 i.v. 60 i.v.
(4 – 6 cycles) d1 d1
(21d cycle) (21d cycle)
Adriamycin/CMF 600 i.v. 40 i.v. 600 i.v. 75 i.v.
(4 cycles A; d1 d1 d1 d1
8 cycles CMF) (21d cycle) (21d cycle) (21d cycle) (21d cycle)
FEC 600 i.v. 600 i.v. 60–75 i.v.
(6 cycles) d1 d1 d1
(21d cycle) (21d cycle) (21d cycle)
NEAT 600 i.v. 40 i.v. 600 i.v. 100 i.v.
(4 cycles epirubicin; d1, d8 d1, d8 d1, d8 d1
4 cycles CMF) (28d cycle) (28d cycle) (28d cycle) (21d cycle)
Adriamycin (4 cycles) 75 i.v.
d1
(21d cycle)
CAF 600 i.v. 600 i.v. 60 i.v.
(6 cycles) d1 d1 d1
(21d cycle) (21d cycle) (21d cycle)
Epirubicin/ CMF 750 i.v. d1 50 i.v. d1 600 i.v. d1 100 i.v. d1
(6 cycles) (21d cycle) (21d cycle) (21d cycle) (21d cycle)
Epirubicin/ CMF 600 i.v. d1 40 i.v. d1 600 i.v. d1 75 i.v. d1
(8 cycles) (21d cycle) (21d cycle) (21d cycle) (21d cycle)
Epirubicin/ CMF 600 i.v. d1 40 i.v. d1 600 i.v. d1 75 i.v. d1
(12 cycles) (28d cycle) (28d cycle) (28d cycle) (28d cycle)
d¼day. Other abbreviations same as in Table 3a.
Table 4 Incidence of neutropenic events
CMF-based regimens Anthracycline-based regimens
CMF/oral d1 – 8 CMF/i.v. d1 – 8 CMF (3-weekly) AC Adriamycin/CMF FEC NEAT Adriamycin CAF Epirubicin/CMF
Patients (n)
a 119 67 71 49 45 36 13 9 7 3
Neutropenic event
(% patients)
28 19 41 12 49 11 54 44 29 0
Dose delay
b
(% patients) 19 13 38 6 40 11 46 33 0 0
Dose reduction
b
(% patients) 11 5 7 4 4 0 31 0 0 0
Hospitalisation
b
(% patients) 6 8 1 8 11 0 8 11 29 0
d¼day.
aIncludes patients who received G-CSF as prophylaxis (CMF-based regimens n¼17; anthracycline-based regimens n¼5).
bDue to neutropenia.
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neutropenic event. Where dose delays and reductions were not
employed, as for CAF, the incidence of hospitalisation was
high. The incidence of neutropenic events was highest in those
receiving the NEAT protocol (epirubicin 100mgm
 2 followed by
CMF).
The incidence of neutropenic events by cycle is shown in
Figure 3. The incidence of neutropenic events appears to increase
significantly after cycle 5. This represents patients receiving NEAT
(eight cycles) and adriamycin/CMF (12 cycles), suggesting that
most events occur in patients on CMF who have previously been
exposed to anthracyline. As with CMF-based regimens, the median
cycle delay due to neutropenia was 7 days, whereas the median
dose reduction due to neutropenia was slightly lower than for CMF
at 20%.
The overall impact of neutropenic events on RDI for patients
receiving anthracycline-based regimens is shown in Figure 4.
Patients who received G-CSF as prophylaxis (n¼5) were excluded
from this analysis. Patients who experienced neutropenic events
received a significantly lower mean RDI than those who did not
experience neutropenic events (87.4 vs 96.3%, Po0.01). The
median (range) RDI was 91.1% (56.7–111%) and 99.3% (66.8–
122%) for patients who experienced and who did not experience
neutropenic events, respectively. Of those patients with neutro-
penic events, 32% did not achieve 85% of the planned DI,
compared with 7% of patients in the group with no events.
Importantly, 9% of patients experiencing neutropenic events failed
to receive 70% of the planned DI (Figure 4).
Risk of subsequent neutropenic events after a first event
For both CMF- and anthracycline-based regimens, the risk of
experiencing a neutropenic event was higher in those patients who
had already experienced an event in an earlier cycle (Table 5). For
CMF-based regimens, the risk increased almost two-fold to a 1:2
risk, whereas for anthracycline-based regimens, the risk increased
almost 2.6-fold to a 3:4 risk.
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Figure 1 Incidence of neutropenic events by cycle: CMF-based
regimens.
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To our knowledge, this is the first time that the incidence of
neutropenic events in patients with primary breast cancer
undergoing adjuvant chemotherapy has been assessed in the UK.
This was not a controlled clinical trial, but an audit designed to
provide an indication of what actually occurred in clinical practice.
As such, we believe it provides an informative insight into our
current practice in the chemotherapeutic management of early
breast cancer.
A wide variety of chemotherapy regimens is currently in use
across the UK for the adjuvant treatment of breast cancer, with
CMF- and anthracycline-based regimens predominating. These
findings are similar to those of the ChemoInsight Project, a large
ongoing US retrospective analysis of 20106 patient records in
which CMF, AC and CAF have so far been the most common
regimens recorded, with CMF being used in 44.2% of patients
(Hayes, 2001).
The audit indicates that neutropenic events occur frequently
during adjuvant chemotherapy for primary breast cancer,
occurring in approximately 30% of patients. Dose delay was found
to be the most common strategy used to cope with neutropenic
events, followed by dose reduction. These findings are again in
accordance with those of the ChemoInsight Project, which
identified 43.1% of 20106 patients experiencing dose delays,
compared with 25.7% experiencing dose reductions (Hayes,
2001).
A median cycle of 7 days seen in the audit reflects our current
practice of delaying chemotherapy for a week in those patients
whose blood counts have failed to recover adequately from prior
chemotherapy. No doubt this reflects a convenience factor
relating to work load and clinic appointment times, and the high
frequency of dose delays may have been the reason for a low
frequency of hospitalisations. Strategies that permit shorter delays
by rechecking blood counts after 2–3 days would probably
ameliorate the impact of dose delay on RDI. However, this may
only be possible in nurse-led clinics, or alternatively, in open-
access chemotherapy units where patients attend daily until blood
counts returned to normal, at which stage chemotherapy could be
administered.
Dose delays and dose reductions have a significant impact on
RDI (Longo et al, 1991), and consequently neutropenic events
were found to have a significant impact on the ability to deliver
planned DI in the audit to such an extent that survival may have
been affected. For both CMF- and anthracycline-based regimens, a
high proportion of patients with neutropenic events did not
achieve 85% of the planned DI compared with the group with no
events. Importantly, 3 and 9% of patients receiving CMF- and
anthracycline-based regimens, respectively, who experienced a
neutropenic event were not able to receive 70% of the planned
dose.
For CMF-based treatment regimens, the incidence of neutro-
penic events (predominantly dose delays) was highest with CMF 3-
weekly regimen. A higher incidence of dose delays due to
haematological toxicity in the CMF 3-weekly vs classical CMF
regimens has also been reported by Engelsman et al (1991). It is
unclear why more events are seen with CMF 3-weekly when
the chemotherapy DI is lower than classical i.v. Day 1, Day 8 CMF,
but it is possible that the patients who received this regimen
attended less experienced centres who were less aggressive in
their dosing schedule. This regimen was also prescribed
more often in district general hospitals, where there may be
fewer available beds. Patients may therefore have had
their chemotherapy delayed/reduced in order to avoid hospitalisa-
tion.
For patients receiving anthracycline-based regimens, the in-
cidence of dose modifications due to neutropenic events was
increased in the higher anthracycline dose protocols, for example,
the NEAT protocol. Where delays and reductions have apparently
been completely avoided, that is, in the CAF group, the
hospitalisation rate is much higher. The incidence of neutropenic
events found with FEC was surprisingly low. This may in part be
due to the relatively lower doses of epirubicin administered over
the first four cycles in FEC vs, for example, the higher doses
administered over the first four cycles in NEAT. Higher doses of
epirubicin have been associated with a significantly higher
incidence of grade 3–4 neutropenia in women with poor
prognosis, node-positive breast cancer, although the higher doses
have also been associated with improved outcome (The French
Adjuvant Study Group, 2001). However, as noted earlier, many of
the neutropenic events occured during the CMF phase of the NEAT
regimens.
Our findings also indicate that patients experiencing one
neutropenic event are much more likely to experience further
events in later cycles. This has been previously reported by
Crawford et al (1991) in patients receiving CAE chemotherapy for
small-cell lung cancer. Patients who have already experienced a
neutropenic event, and in whom maintenance of DI is important,
may benefit from haematopoietic growth factors such as G-CSF
when given as secondary prophylaxis (American Society of Clinical
Oncology, 1994, 1996; Ozer et al, 2000). In breast cancer
patients experiencing insufficient neutrophil recovery during CMF
chemotherapy, a 10-day course of G-CSF has been shown to
enhance neutrophil recovery, and help maintain scheduled che-
motherapy DI (de Graaf et al, 1996). However, from this audit it
appears that the administration of G-CSF to limit the impact of
neutropenic events occurs infrequently (o6%), much less than
European and American counterparts where RDI is also higher
(Hayes, 2001). Many clinicians may not perceive neutropenia to be
an issue when administering adjuvant chemotherapy, and it is
unlikely that, at the time, much consideration was given to the
effects of these strategies on RDI and OS, when survival is such a
distant end point. As always, cost issues are likely to play a major
role in limiting the use of G-CSF, but there is increasing evidence
that the costs of using G-CSF may be offset by reducing the cost of
delays and hospitalisations (Seifeldin and Schultz 1998; Silber et al,
1998a,b).
In conclusion, neutropenic events have a significant impact
on the ability to deliver planned chemotherapy DI in the
adjuvant treatment of breast cancer, and these events may
therefore have an impact upon patient survival. Further evaluation
of the cost effectiveness of interventions such as G-CSF that
limit neutropenic complications should be performed in order
that such strategies, if cost effective, are not withheld on the basis
of acquisition costs alone. Many clinicians may not be aware of
the extent to which dose modifications impact upon overall DI,
and should bear in mind their potential impact on survival
when considering the best strategy to maximise delivery of
chemotherapy.
Table 5 Risk of subsequent neutropenic events after a first event
Regimen
% patients
experiencing at
least one neutropenic
event
% patients
experiencing a
neutropenic event
after a first event
CMF-based (n¼257) 29 56
Anthracycline-based (n¼165)
a 28 72
aIn total, 162 patients receiving anthracycline-based regimens and three patients
receiving either epirubicin, epirubicin/cyclophosphamide or docetaxel.
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Appendix
The UK Breast Cancer Neutropenia Audit Group consisted of the
following investigators: S Hima, Jersey General Hospital, Jersey; D
Spooner, Dudley Road Hospital, Birmingham; P Barrett-Lee,
Velindre Hospital, Cardiff; R Coleman, Weston Park Hospital,
Sheffield; M Lind, A Maraveys, A Chaterverdi, Princes Royal
Hospital, Hull; J Barrett, Royal Berkshire Hospital, Reading; P
Simmonds, Southampton General Hospital, Southampton; N
Davidson, North Middlesex Hospital, Middlesex; R Pettengell, J
Mansi, St George’s Hospital, London; I Smith, Royal Marsden
Hospital, London.
Impact of neutropenia on delivering planned chemotherapy
RCF Leonard et al
2068
British Journal of Cancer (2003) 89(11), 2062–2068 & 2003 Cancer Research UK
C
l
i
n
i
c
a
l